Vertex Pharmaceuticals announced a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access CASGEVY (exagamglogene autotemcel). This agreement follows a prior reimbursement agreement for transfusion-dependent beta thalassemia (TDT) patients in August 2024.
The National Institute for Health and Care Excellence (NICE) issued positive guidance recommending CASGEVY’s use within the NHS. This ensures that eligible SCD patients in England now have access to this CRISPR/Cas9 gene-edited therapy.
Vertex is continuing to engage with experienced hospitals across England to establish a network of independently operated authorized treatment centers. This agreement is a significant step in bringing this one-time treatment to patients who have long awaited therapies addressing the underlying cause of their devastating disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.